Sunfox Technologies Raises $7 Million: How a Dehradun Startup Is Taking Cardiac Care to the Last Mile

From a portable ECG to a connected cardiac-care ecosystem, Sunfox Technologies is betting that the future of heart diagnostics will be smaller, smarter and far more accessible.

A heart attack does not wait for a hospital appointment. It does not care whether a patient lives in a metropolitan city or a remote village, and it certainly does not wait for the nearest specialist to become available.

For millions of patients, however, the biggest challenge is not necessarily the absence of treatment. It is the distance between the first symptom and the first accurate diagnosis.

That is the gap that Sunfox Technologies has spent years trying to close.

The Dehradun-based medtech startup, which began as an R&D venture in Uttarakhand, has now raised $7 million (approximately ₹67 crore) in Series A funding, marking the largest funding round in the company’s history. The round was led by investor Ashish Kacholia, along with Lashit Sanghvi, Alchemy Capital and 3one4 Capital. The company plans to use the capital to expand across India, build its international go-to-market capabilities, scale its organisation and accelerate research and development. 

But this is more than another funding announcement in India’s increasingly crowded health-tech ecosystem.

Sunfox is attempting to solve a much harder problem: how to make clinically useful cardiac diagnostics available where conventional healthcare infrastructure cannot easily reach.

The Big Idea Behind Sunfox Technologies

Founded in 2016 by Rajat Jain, Arpit Jain, Sabit Rawat, Nitin Chandola and Saurabh Badola, Sunfox was born from a deeply personal motivation.

According to the company and reporting around its latest fundraise, the founders began exploring cardiac-care technology after losing a friend and witnessing the challenges associated with timely cardiac assessment. Their objective was to reduce the time between a cardiac emergency and appropriate medical intervention.

That objective eventually led to Spandan, Sunfox’s portable ECG platform.

The proposition is straightforward but significant: instead of requiring patients to travel to a hospital or diagnostic centre for every ECG, a compact device can capture cardiac signals closer to the patient and connect those results with healthcare professionals.

Sunfox has developed Spandan solutions for home users, clinics, hospitals and public-health programmes. Its broader Spandan One ecosystem adds digital connectivity, allowing frontline healthcare workers to capture ECGs and transmit them for professional review.

The result is an approach that combines three elements: portable hardware, connected software and access to medical expertise.

What Makes Spandan Different?

Traditional ECG machines are generally associated with hospitals, clinics and diagnostic facilities. Sunfox’s strategy is to make ECG testing considerably more portable.

The company’s latest product lineup includes Spandan 4.0, Spandan Neo, Spandan Pro and Spandan Ultra 12L, targeting different use cases from home monitoring to professional clinical environments. 

According to Sunfox, Spandan 4.0 weighs just 14.5 grams, can perform sequential 12-lead-capable ECG recording and works through a smartphone. The company also says recording and PDF report generation can work offline after initial setup.

The larger opportunity, however, is not simply making an ECG machine smaller.

It is making the diagnostic workflow portable.

With Spandan One, healthcare workers can conduct ECG tests, enter patient information, transmit reports and receive feedback from doctors. The platform has also introduced an option for AI interpretation alongside doctor review. 

That creates the possibility of a hub-and-spoke healthcare model: a health worker at a primary or community health centre performs the ECG, while a doctor or cardiologist located elsewhere can review the result.

For regions with limited specialist availability, that distinction can be crucial.

A Major Validation Moment Came in July

Sunfox’s funding announcement arrived after a particularly important period for the company’s clinical research.

In July 2026, three studies involving the company’s ECG technology were published in medical journals, according to Sunfox’s clinical research library.

One study published in Biomedical Physics & Engineering Express evaluated the Spandan Ultra 12L against a standard Philips PageWriter 12-lead ECG system. The study involved 330 participants and reported no significant differences between the two devices across ECG intervals, amplitudes and durations. 

Another study, published in the International Journal of the Cardiovascular Academy, examined the diagnostic accuracy of the smartphone-based Spandan Ultra 12L for common bradycardias, tachycardias and ectopic arrhythmias. The prospective comparative study involved 321 symptomatic adults in Dehradun, with cardiologist interpretation serving as the reference standard. 

A third study, published in the Journal of Electrocardiology, evaluated the agreement between Spandan Pro and conventional ECG against coronary angiography in 109 myocardial-infarction patients. 

These studies matter because medtech companies cannot build credibility on portability alone.

A device may be compact and convenient, but clinical adoption ultimately depends on whether healthcare professionals can trust the information it produces.

For Sunfox, the recent research provides an important layer of clinical evidence as the company prepares to enter more international markets.

From the Himalayas to Rural Haryana

Perhaps the clearest example of Sunfox’s real-world strategy has emerged in Haryana.

The state has been deploying Spandan One as part of a tele-ECG network, connecting government health facilities with clinical review capabilities.

By September 2026, the initiative had equipped nearly 600 government health facilities, including primary and community health centres. Data reported as of September 17 showed more than 33,854 ECG tests and 1,342 critical cardiac cases detected. 

The model is particularly important because it shifts the starting point of cardiac care.

Instead of asking a rural patient to travel first and receive a diagnosis later, the diagnostic process can begin at the local health centre.

A frontline healthcare worker can capture an ECG, transmit the information and receive clinical input, potentially allowing patients requiring urgent treatment to be identified and referred faster.

That is the underlying value proposition of tele-ECG: move diagnosis closer to the patient rather than moving every patient closer to a specialist.

Sunfox Expands Doctor Access to 24/7

In another notable development in September, Sunfox announced that its doctor-review service became available 24/7 from September 28, 2026.

The service allows users to submit recorded ECGs through the Spandan application for expert review, with the company stating that users can receive a doctor’s review within 15 minutes. 

For a cardiac-care platform, the timing is particularly relevant.

Heart-related symptoms rarely appear according to business hours. Expanding doctor review around the clock strengthens Sunfox’s attempt to position Spandan not merely as a diagnostic device but as part of a broader care pathway.

It also illustrates the direction in which the company is moving: from hardware to healthcare infrastructure.

The $7 Million Funding Round

The October funding round is the biggest financial milestone in Sunfox’s journey so far.

The company has raised $7 million in Series A funding, equivalent to roughly ₹67 crore, from Ashish Kacholia, Lashit Sanghvi, Alchemy Capital and 3one4 Capital. 

The new capital is expected to support four major priorities:

• • Expanding deeper across India

• • Building international go-to-market capabilities

• • Scaling the organisation

• • Increasing investment in research and development

Sunfox also plans to strengthen its regulatory, distribution and commercial capabilities in international markets, including the United States, Europe and Africa. The company says it already has regulatory approvals in India, Ghana, Kenya, Tanzania and South Africa, while pursuing clearances in the US and European Union. 

For investors, this represents an important transition.

Sunfox is moving from proving that its technology can work to demonstrating that it can scale commercially and clinically across markets.

A Startup Built Around Access, Not Just Technology

According to company figures reported with the latest funding announcement, approximately 60,000 Spandan devices have been deployed across India, reaching more than 20,000 villages. Sunfox also says Spandan One is used to screen approximately 5 million patients annually across healthcare settings. 

Those numbers should be viewed as company-reported figures rather than independently audited market statistics, but they illustrate the scale Sunfox is targeting.

The company’s model also reflects an important shift taking place across India’s health-tech sector.

The next generation of healthcare startups may not necessarily be built around consumer apps alone. Instead, some of the most consequential businesses could emerge at the intersection of medical devices, AI, connectivity, clinical workflows and public healthcare infrastructure.

Sunfox sits squarely in that intersection.

The Road Ahead

The $7 million Series A gives Sunfox the resources to pursue a considerably larger ambition.

International expansion will bring new challenges, including regulatory approvals, clinical validation, distribution, reimbursement and establishing trust among doctors and healthcare institutions.

The company will also have to demonstrate that its model can remain financially sustainable while serving precisely the populations that traditional healthcare systems often struggle to reach.

Yet the opportunity is significant.

In July, Sunfox was strengthening its clinical evidence. In September, its technology was being used in a large-scale rural tele-ECG programme in Haryana, while its doctor-review service moved to 24/7 availability. By October, the company had secured its largest funding round to date.

Taken together, these developments show a startup progressing through several stages at once: clinical validation, public-health deployment, product expansion and international scaling.

Conclusion: Can Sunfox Put Cardiac Care Within Everyone’s Reach?

Sunfox Technologies began in Dehradun with a relatively ambitious question: could technology reduce the time between a cardiac emergency and the right medical decision?

Nearly a decade later, the company is attempting to turn that idea into a scalable healthcare ecosystem.

Its $7 million Series A is not simply capital for growth. It is a vote of confidence in the idea that cardiac diagnostics can become more portable, connected and accessible.

The company’s biggest opportunity may ultimately lie beyond the device itself.

If Spandan can reliably connect a patient, a frontline health worker and a doctor regardless of geography  Sunfox could help change where cardiac care begins.

And that may be the most compelling part of its story.

The future of cardiac care may not begin in the hospital. It may begin with a small device, a smartphone and a healthcare worker standing much closer to the patient.

Written By
Divya